GlassScriptPhysician profile
Ashley Manalel
NPI 1528547346
$4,162.77
in general payments reported to CMS, 2019-2025
40 companies · $1,991 in 2025
The $1,991 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $82.97 · 2024: $1,949 · 2025: $1,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,933 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,933.39 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $692.62 | 2023-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $338.80 | 2024-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $238.14 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $228.72 | 2024-2025 | Tecentriq, Itovebi |
| Boston Scientific Corporation | $211.77 | 2025 | Ams 700 |
| Janssen Biotech, INC. | $203.28 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Sobi, INC | $195.19 | 2022-2025 | |
| Amgen INC. | $191.14 | 2024 | Evenity |
| Exelixis INC. | $176.81 | 2024-2025 | Cabometyx |
| Incyte Corporation | $156.42 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Janssen Pharmaceuticals, INC | $144.38 | 2024 | Xarelto |
| Pfizer INC. | $139.95 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $132.77 | 2025 | |
| Abbvie INC. | $124.23 | 2024-2025 | |
| Novo Nordisk INC | $118.30 | 2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $98.25 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $73.69 | 2024 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $72.95 | 2024-2025 | Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $62.38 | 2024-2025 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $59.76 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Genmab U.S., INC. | $43.43 | 2024-2025 | Epkinly |
| Stemline Therapeutics INC. | $41.07 | 2024 | Orserdu |
| Genzyme Corporation | $34.39 | 2025 | |
| Eisai INC. | $32.10 | 2024 | |
| Celltrion USA INC. | $31.97 | 2023 | Vegzelma |
| Jazz Pharmaceuticals INC. | $28.69 | 2024 | |
| Beone Medicines USA, INC. | $25.88 | 2025 | Brukinsa |
| Seagen INC. | $25.22 | 2023 | Padcev |
| Teleflex LLC | $23.67 | 2024 | Arrow |
| Bard Peripheral Vascular, INC. | $21.59 | 2025 | Peritx |
| Tersera Therapeutics LLC | $21.23 | 2025 | Xermelo |
| Myriad Genetic Laboratories, INC. | $21.22 | 2024 | Myrisk |
| Syndax Pharmaceuticals, INC. | $20.84 | 2025 | |
| Array Biopharma INC | $20.77 | 2024 | Xalkori, Lorbrena, Braftovi |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.68 | 2024 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $19.42 | 2025 | Monoferric |
| Cycle Pharmaceuticals INC | $19.20 | 2025 | Phyrago |
| Adc Therapeutics America, INC. | $18.03 | 2025 | |
| Tempus Ai, INC | $15.02 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Manalel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.